2.305
前日終値:
$2.26
開ける:
$2.31
24時間の取引高:
265.04K
Relative Volume:
0.63
時価総額:
$145.42M
収益:
$4.39M
当期純損益:
$-22.40M
株価収益率:
-4.5214
EPS:
-0.5098
ネットキャッシュフロー:
$-22.79M
1週間 パフォーマンス:
+31.16%
1か月 パフォーマンス:
+7.18%
6か月 パフォーマンス:
+126.96%
1年 パフォーマンス:
+470.20%
Equillium Inc Stock (EQ) Company Profile
Compare EQ vs VRTX, REGN, ARGX, ALNY, RVMD
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
|
EQ
Equillium Inc
|
2.30 | 142.89M | 4.39M | -22.40M | -22.79M | -0.5098 |
|
VRTX
Vertex Pharmaceuticals Inc
|
435.92 | 110.28B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
634.42 | 66.98B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
808.61 | 50.15B | 4.16B | 1.29B | 734.26M | 19.58 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
295.50 | 39.71B | 4.29B | 577.22M | 641.34M | 4.2086 |
|
RVMD
Revolution Medicines Inc
|
154.89 | 32.22B | 742.00K | -1.37B | -1.07B | -7.0731 |
Equillium Inc Stock (EQ) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-23 | 開始されました | Oppenheimer | Outperform |
| 2026-04-16 | 開始されました | B. Riley Securities | Buy |
| 2026-04-14 | 開始されました | Raymond James | Strong Buy |
| 2026-04-07 | 開始されました | Cantor Fitzgerald | Overweight |
| 2026-03-13 | 開始されました | Roth Capital | Buy |
| 2026-02-25 | 開始されました | Stifel | Buy |
| 2025-03-28 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2021-10-29 | 再開されました | Stifel | Buy |
| 2021-09-15 | 開始されました | Cantor Fitzgerald | Overweight |
| 2020-07-14 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-07-10 | 再開されました | Stifel | Buy |
| 2019-02-22 | 開始されました | SVB Leerink | Outperform |
すべてを表示
Equillium Inc (EQ) 最新ニュース
EQ News | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
Equillium to Host Virtual Investor Event to Share New - GlobeNewswire
EQ Stock Chart | EQUILLIUM INC (NASDAQ:EQ) - ChartMill
ADAR1 entities hold ~9–10% of Equillium (EQ) as of Mar 31, 2026 - Stock Titan
Decheng Capital & Xiangmin Cui report 5.73M EQ shares (EQ) - Stock Titan
Oppenheimer Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $7 - Moomoo
Equillium: Compliance, Operational and Market Risks Cloud Long-Term Outlook for Shareholders - TipRanks
TradingKey - TradingKey
Equillium, Inc. Stock 12‑Month Price Target Cut to $6.38, Implies 176% Upside - TradingView
Equillium (EQ) Advances Research on EQ504 for Immune Modulation - GuruFocus
Is Equillium (EQ) 2210.0% Overvalued After Q1 2026 Earnings? GF - GuruFocus
Equillium Inc. (NASDAQ:EQ) Reports Narrower Q1 Loss But Slight EPS Miss as EQ504 Study Timeline Confirmed - ChartMill
Equillium Reports First Quarter 2026 Financial Results and Corporate Highlights - The Manila Times
Equillium, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 - marketscreener.com
Equillium (NASDAQ: EQ) trims Q1 2026 loss, raises $35M and funds runway into 2029 - Stock Titan
Equillium (NASDAQ: EQ) trims Q1 2026 loss and extends cash runway into 2029 - Stock Titan
Number of shareholders of Equillium, Inc. – NASDAQ:EQ - TradingView
Number of shareholders of Equillium, Inc. – DUS:0FY - TradingView
Equillium Inc expected to post a loss of 4 cents a shareEarnings Preview - TradingView
EQ (Equillium) EPS beats by 35% but shares fall 1.4% as investors eye pipeline milestones over near-term losses.Trending Volume Leaders - newser.com
What separates Equillium (EQ) from the pack? (-1.38%) 2026-05-07Momentum Investing - Newser
Aberdeen Group (NASDAQ: EQ) shows 3.35M-share stake in Equillium - Stock Titan
Should you add Equillium (EQ) to your watchlist today? (Bearish Momentum) 2026-05-05High Interest Stocks - Newser
Equillium, Inc. (NASDAQ:EQ) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
Equillium Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Equillium, Inc. Grants Inducement Stock Options to New Employees Under 2024 Inducement Plan - Quiver Quantitative
Two new Equillium hires receive options for 800,000 shares - Stock Titan
B Riley Securities initiates coverage of Equillium (EQ) with buy recommendation - MSN
Equillium (EQ) price target increased by 120.00% to 5.61 - MSN
Oppenheimer Initiates Equillium(EQ.US) With Buy Rating, Announces Target Price $7 - Moomoo
Equillium (NASDAQ:EQ) Coverage Initiated by Analysts at Oppenheimer - MarketBeat
Oppenheimer Initiates Coverage on Equillium With Outperform Rating, $7 Price Target - marketscreener.com
Oppenheimer initiates Equillium stock with Outperform on UC drug By Investing.com - Investing.com Australia
Oppenheimer initiates Equillium stock with Outperform on UC drug - Investing.com
Equillium initiated with an Outperform at Oppenheimer - TipRanks
Is It Stable or Volatile | Equillium Inc. Posts 35.3% EPS Beat, Narrower Net Loss Vs EstimatesElite Trading Signals - Cổng thông tin điện tử tỉnh Lào Cai
Roth MKM Maintains Equillium(EQ.US) With Buy Rating, Maintains Target Price $12 - Moomoo
Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event - The Manila Times
EQ Reiterated by Roth Capital -- Price Target Maintained at $12 - GuruFocus
Equillium (EQ) price target increased by 10.71% to 7.90 - MSN
Roth Mkm Reiterates Buy Rating for Equillium (NASDAQ:EQ) - MarketBeat
[EFFECT] Equillium, Inc. SEC Filing - Stock Titan
Here’s what Roth Capital thinks of Equillium (EQ) stock - MSN
EQ Upgraded by B. Riley Securities -- Price Target Announced at $6.00 - GuruFocus
Equillium Inc (EQ) 財務データ
収益
当期純利益
現金流量
EPS
Equillium Inc (EQ) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| Zedelmayer Christine | Sr. Vice President and COO |
Mar 13 '26 |
Sale |
2.50 |
120,312 |
300,816 |
62,586 |
大文字化:
|
ボリューム (24 時間):